DDInter31 DDInter1676
The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson].[A229833,A229838] Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Adenosine {u} (Compound) resembles {v} (Compound) Azacitidine
Adenosine {u} (Compound) resembles {v} (Compound) Nelarabine
Adenosine {u} (Compound) binds {v} (Gene) ADORA2B
Adenosine {u} (Compound) is included by {v} (Pharmacologic Class) Adenosine Receptor Agonists
Adenosine {u} (Compound) downregulates {v} (Gene) KIF14
Adenosine {u} (Compound) causes {v} (Side Effect) Atrioventricular block
Adenosine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Adenosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cilostazol
Adenosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caffeine
Adenosine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Adenosine (Compound) resembles Azacitidine (Compound)
Adenosine (Compound) resembles Nelarabine (Compound)
Adenosine (Compound) binds ADORA2B (Gene)
Adenosine (Compound) is included by Adenosine Receptor Agonists (Pharmacologic Class)
Adenosine (Compound) downregulates KIF14 (Gene)
Adenosine (Compound) causes Atrioventricular block (Side Effect)
Adenosine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Caffeine
Adenosine may lead to a major life threatening interaction when taken with Ribociclib